Agilent’s expertise provides a range of analytical solutions to both identify and quantify microplastics in the environment.
In our Microplastics Symposium, hear from industry experts and peers working within the field of Microplastics.
With a mixture of live talks across various topic areas and product demonstrations, this event is a great opportunity to uncover more about microplastics analysis in the lab. We will also have our experts available to chat live on the day, allowing you to further increase your knowledge and skills on this topical issue.
What topic areas can you expect to see on the day?
- Microplastics Analysis with the 8700 LDIR with a focus on the marine environment;
- Quantification of Microplastics with GC/MSD;
- Current activities in the world of standardization;
- Microplastics Analysis with the GC/Q-TOF;
- And more.
The Agilent TRS100 Raman system is ideal for fast assay of tablets, capsules, and other dosage forms. Transmission Raman technology from Agilent enables simple method-development and deployment in QC applications. It is easy to implement in analytical laboratories and production areas, and has regulatory approvals for content uniformity (CU), assay, and identification (ID) applications. This online seminar provides a comprehensive introduction to the Transmission Raman technology and the Agilent TRS100 Raman system in the pharmaceutical quality-control applications.
Yanqia Wang, PhD, Application Engineer, Molecular Spectroscopy, Agilent Technologies, Inc.
Dr. Yanqia Wang started working for Agilent Technologies Inc. as a FTIR application Engineer in 2013, providing pre-&post-sale application support. The products he covers from Bench-top FTIR microscopes to various Mobile FTIR spectrometers. Dr. Wang received his PhD of analytical chemistry from Duke University in 2004, doing dynamic IR spectroscopy research. Then he joined Fitzpatrick Center for Photonics at Duke University, doing Tissue Raman spectrometer instrumentation. Since 2007, Dr. Wang worked for Avery Dennison Corp. as a spectroscopist, providing molecular analytical support to the research & development.
Individuals vary widely in their drug responses, which can be dangerous and expensive due to significant treatment delays and adverse effects. Growing evidence implicates the gut microbiome in this variability, however the molecular mechanisms remain mostly unknown.
To systematically map the drug metabolizing capacity of the gut microbiota and assess its potential contribution to drug metabolism, the speaker measured the ability of 76 diverse human gut bacteria to metabolize each of 271 oral drugs. They found that two-thirds of these drugs are chemically modified by at least one of the tested microbes.
Through combination of high-throughput bacterial genetics with mass spectrometry-based metabolomics, the speaker systematically identified drug-metabolizing microbial enzymes. These proteins better explain the drug metabolizing capacity of bacterial strains than their phylogenetic classification.
The speaker further demonstrated that the abundance of homologs of these proteins predict the capacity of complete human gut communities to metabolize the targeted drugs. These causal links between microbiota gene content and metabolic activities connect inter-individual microbiome variability to interpersonal differences in drug metabolism, which has translatable potential on medical therapy and drug development across multiple disease indications.
Learn how to:
- Employ high-throughput LC-MS analysis to map gut microbial metabolism
- Combine bacterial genetics with high-throughput LC-MS analysis to identify metabolic enzymes in the gut microbiome
- Integrate in vitro drug metabolism of gut bacteria, genomic information, and metagenomic data.